vs
Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and Dexcom (DXCM). Click either name above to swap in a different company.
Dexcom is the larger business by last-quarter revenue ($1.3B vs $885.8M, roughly 1.4× BWX Technologies, Inc.). Dexcom runs the higher net margin — 21.2% vs 10.5%, a 10.7% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 18.7%). Over the past eight quarters, BWX Technologies, Inc.'s revenue compounded faster (21.1% CAGR vs 12.0%).
BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
BWXT vs DXCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $885.8M | $1.3B |
| Net Profit | $93.0M | $267.3M |
| Gross Margin | — | 62.9% |
| Operating Margin | 10.4% | 25.6% |
| Net Margin | 10.5% | 21.2% |
| Revenue YoY | 18.7% | 21.6% |
| Net Profit YoY | 30.9% | 153.6% |
| EPS (diluted) | $1.02 | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $885.8M | $1.3B | ||
| Q3 25 | $866.3M | $1.2B | ||
| Q2 25 | $764.0M | $1.2B | ||
| Q1 25 | $682.3M | $1.0B | ||
| Q4 24 | $746.3M | $1.1B | ||
| Q3 24 | $672.0M | $994.2M | ||
| Q2 24 | $681.5M | $1.0B |
| Q1 26 | — | $267.3M | ||
| Q4 25 | $93.0M | $267.3M | ||
| Q3 25 | $82.1M | $283.8M | ||
| Q2 25 | $78.4M | $179.8M | ||
| Q1 25 | $75.5M | $105.4M | ||
| Q4 24 | $71.0M | $151.7M | ||
| Q3 24 | $69.5M | $134.6M | ||
| Q2 24 | $73.0M | $143.5M |
| Q1 26 | — | 62.9% | ||
| Q4 25 | — | 62.9% | ||
| Q3 25 | 21.8% | 60.5% | ||
| Q2 25 | 25.1% | 59.5% | ||
| Q1 25 | 24.2% | 56.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | 24.4% | 59.7% | ||
| Q2 24 | 24.7% | 62.4% |
| Q1 26 | — | 25.6% | ||
| Q4 25 | 10.4% | 25.6% | ||
| Q3 25 | 13.1% | 20.1% | ||
| Q2 25 | 13.4% | 18.4% | ||
| Q1 25 | 14.2% | 12.9% | ||
| Q4 24 | 12.4% | 17.0% | ||
| Q3 24 | 14.4% | 15.3% | ||
| Q2 24 | 14.5% | 15.7% |
| Q1 26 | — | 21.2% | ||
| Q4 25 | 10.5% | 21.2% | ||
| Q3 25 | 9.5% | 23.5% | ||
| Q2 25 | 10.3% | 15.5% | ||
| Q1 25 | 11.1% | 10.2% | ||
| Q4 24 | 9.5% | 13.6% | ||
| Q3 24 | 10.3% | 13.5% | ||
| Q2 24 | 10.7% | 14.3% |
| Q1 26 | — | $0.67 | ||
| Q4 25 | $1.02 | $0.67 | ||
| Q3 25 | $0.89 | $0.70 | ||
| Q2 25 | $0.85 | $0.45 | ||
| Q1 25 | $0.82 | $0.27 | ||
| Q4 24 | $0.77 | $0.37 | ||
| Q3 24 | $0.76 | $0.34 | ||
| Q2 24 | $0.79 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $499.8M | $917.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $2.7B |
| Total Assets | $4.3B | $6.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $917.7M | ||
| Q4 25 | $499.8M | $917.7M | ||
| Q3 25 | $79.6M | $1.8B | ||
| Q2 25 | $37.0M | $1.2B | ||
| Q1 25 | $55.4M | $904.9M | ||
| Q4 24 | $74.1M | $606.1M | ||
| Q3 24 | $35.5M | $621.2M | ||
| Q2 24 | $48.3M | $939.2M |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $1.2B | $2.7B | ||
| Q3 25 | $1.2B | $2.7B | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.1B | $2.3B | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | $1.1B | $2.0B | ||
| Q2 24 | $998.5M | $2.4B |
| Q1 26 | — | $6.3B | ||
| Q4 25 | $4.3B | $6.3B | ||
| Q3 25 | $3.8B | $7.5B | ||
| Q2 25 | $3.7B | $7.3B | ||
| Q1 25 | $3.1B | $6.8B | ||
| Q4 24 | $2.9B | $6.5B | ||
| Q3 24 | $2.9B | $6.4B | ||
| Q2 24 | $2.8B | $6.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $127.0M | — |
| Free Cash FlowOCF − Capex | $56.8M | — |
| FCF MarginFCF / Revenue | 6.4% | — |
| Capex IntensityCapex / Revenue | 7.9% | — |
| Cash ConversionOCF / Net Profit | 1.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | $295.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $127.0M | $294.0M | ||
| Q3 25 | $143.2M | $659.9M | ||
| Q2 25 | $159.0M | $303.0M | ||
| Q1 25 | $50.6M | $183.8M | ||
| Q4 24 | $276.9M | $301.4M | ||
| Q3 24 | $32.6M | $199.5M | ||
| Q2 24 | $65.9M | $279.4M |
| Q1 26 | — | — | ||
| Q4 25 | $56.8M | $192.1M | ||
| Q3 25 | $94.9M | $579.4M | ||
| Q2 25 | $126.3M | $208.9M | ||
| Q1 25 | $17.3M | $96.8M | ||
| Q4 24 | $224.4M | $176.8M | ||
| Q3 24 | $-7.7M | $88.3M | ||
| Q2 24 | $35.5M | $213.3M |
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | 15.3% | ||
| Q3 25 | 11.0% | 47.9% | ||
| Q2 25 | 16.5% | 18.1% | ||
| Q1 25 | 2.5% | 9.3% | ||
| Q4 24 | 30.1% | 15.9% | ||
| Q3 24 | -1.1% | 8.9% | ||
| Q2 24 | 5.2% | 21.2% |
| Q1 26 | — | — | ||
| Q4 25 | 7.9% | 8.1% | ||
| Q3 25 | 5.6% | 6.7% | ||
| Q2 25 | 4.3% | 8.1% | ||
| Q1 25 | 4.9% | 8.4% | ||
| Q4 24 | 7.0% | 11.2% | ||
| Q3 24 | 6.0% | 11.2% | ||
| Q2 24 | 4.5% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.37× | 1.10× | ||
| Q3 25 | 1.74× | 2.33× | ||
| Q2 25 | 2.03× | 1.69× | ||
| Q1 25 | 0.67× | 1.74× | ||
| Q4 24 | 3.90× | 1.99× | ||
| Q3 24 | 0.47× | 1.48× | ||
| Q2 24 | 0.90× | 1.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BWXT
| Nuclear Component Program | $436.4M | 49% |
| Nuclear Manufacturing | $134.8M | 15% |
| Cost Plus Fee | $116.1M | 13% |
| Uranium And Nuclear Services | $103.8M | 12% |
| Commercial Operations | $49.0M | 6% |
| Commercial Operations Segment | $33.7M | 4% |
| Transferred At Point In Time | $1.3M | 0% |
DXCM
Segment breakdown not available.
